Pharmaceuticals

AB Science has secured a US patent until 2042 for masitinib, a targeted therapy for advanced prostate cancer, offering new hope where few options exist.

Model N's acquisition of Kalderos targets the chaotic 340B drug discount program, a system where 99% of pharma leaders lack real-time data visibility.

A new network aims to speed up clinical trials by recruiting patients from med spas and longevity clinics. Is this the future of medicine or a risky new frontier?

With 180-day exclusivity, Lupin's generic hypertension drug launch is set to disrupt a $53M market, highlighting a masterclass in pharmaceutical strategy.

A new report reveals which cannabis brands dominate AI search, just as federal rescheduling creates chaos and opportunity. But with AI often refusing to answer, who wins?

Hearst and NYU Langone's star-studded Health Lab reveals a strategic pivot from fitness to holistic wellness, tapping a new market of longevity and vulnerability.

Bristol Myers Squibb appoints Mayada Al-Ahmad, a 24-year pharma veteran, to lead its Saudi and Gulf operations, aligning with the region's ambitious health goals.

A key regulatory win in Abu Dhabi opens a new international front for NeOnc's war on brain tumors, backed by novel science and significant insider buying.

A new partnership aims to replace needles with pills for a powerful class of drugs, using advanced AI to solve a multi-billion dollar challenge in medicine.

Laprophan's acquisition of Rivopharm is more than a deal; it's a strategic blueprint for emerging market players aiming for the global pharmaceutical stage.

Gelteq aims to replace needles with its ingestible gel, targeting diabetes and more. But can it balance this lofty goal with near-term revenue and tight finances?

An Israeli biotech just published a patent for a 'mucoadhesive' gel that makes drugs stick inside the nose. It's a key step in a multi-billion dollar race.

Insilico Medicine's AI-designed drug, ISM8969, enters human trials, targeting chronic neuroinflammation by crossing the elusive blood-brain barrier.

The communications firm adds three seasoned experts, a strategic move to guide biotech and pharma clients through increasingly volatile capital markets.

As giants rule the obesity market, small-cap MetaVia pitches a novel dual-agonist and a first-in-class MASH drug. Can its science win the day?

With a new $400M debt facility, Dyne Therapeutics is accelerating two promising drugs for DMD and DM1, showcasing the power of strategic, non-dilutive financing.

With a promising drug and a fortified war chest, Trevi Therapeutics’ upcoming conference tour is a calculated move to conquer a vast, unmet medical need.

A landmark grant and trial expansion signal a pivotal shift in Parkinson's research, blending genetic targeting, global collaboration, and digital health.

Verastem Oncology's combo therapy posts impressive early data in a notoriously deadly cancer, revealing a shrewd strategy for tackling drug resistance.

New data on ersodetug reveals a calculated strategy to conquer hyperinsulinism, balancing patient hope with the harsh realities of the biotech market.